Browse by Audience
Skip to content
Papers of the Week
Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
Abstract
OnabotulinumtoxinA is effective in treating chronic migraine (CM), but there are limited data assessing how allodynia affects preventive treatment responses. This subanalysis of the 108-week, multicenter, open-label COMPEL Study assessed the efficacy and safety of onabotulinumtoxinA in people with CM with and without allodynia.